October 5, 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo + Yervoy Regimen
Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.